Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2025 20:13 ET | Source: Novartis Pharma AG

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation...
March 31, 2025 01:00 ET | Source: Novartis Pharma AG

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of...
March 28, 2025 12:52 ET | Source: Novartis Pharma AG

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)...
March 25, 2025 02:15 ET | Source: Novartis Pharma AG

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients...
March 20, 2025 19:11 ET | Source: Novartis Pharma AG

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Phase III study showed sustained proteinuria reduction at one year with favorable safety1Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause...
March 19, 2025 09:00 ET | Source: Novartis Pharma AG

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

Treatment with investigational OAV101 IT led to statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in sham control armSafety findings were consistent in both treatment-naïve...
March 07, 2025 09:11 ET | Source: Novartis Pharma AG

Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut

Die Aktionärinnen und Aktionäre genehmigten die 28. Dividendenerhöhung in Folge. Für 2024 wird die Dividende auf CHF 3.50 (+6,1%) je Aktie erhöht, was einer Rendite von 3,5% entspricht1Die...
March 07, 2025 09:11 ET | Source: Novartis Pharma AG

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board...
February 28, 2025 09:00 ET | Source: Novartis Pharma AG

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III...
February 28, 2025 07:39 ET | Source: Novartis Pharma AG

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 ...

Next Page keyboard_arrow_right